Colgate-Palmolive (NYSE:CL) had its price target raised by investment analysts at Morgan Stanley from $68.00 to $72.00 in a research note issued on Monday, BenzingaRatingsTable reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price target would indicate a potential downside of 3.36% from the stock’s current price.
Several other research analysts have also weighed in on the stock. Wells Fargo & Co set a $29.00 target price on shares of Establishment Labs and gave the stock a “buy” rating in a research note on Friday, July 12th. JPMorgan Chase & Co. set a €118.00 ($137.21) price objective on shares of Deutsche Boerse and gave the company a “neutral” rating in a research note on Monday, April 29th. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. Bank of America set a $80.00 price objective on shares of Colgate-Palmolive and gave the company a “buy” rating in a research note on Friday, July 12th. Finally, Macquarie started coverage on shares of Rollins in a research note on Monday, April 29th. They issued a “neutral” rating and a $38.90 price objective for the company. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have issued a buy rating to the stock. Colgate-Palmolive currently has a consensus rating of “Hold” and a consensus target price of $71.94.
Shares of CL stock opened at $74.50 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.74 and a debt-to-equity ratio of 32.25. The stock has a market capitalization of $63.86 billion, a price-to-earnings ratio of 25.08, a PEG ratio of 4.87 and a beta of 0.78. The stock’s 50-day moving average is $72.74. Colgate-Palmolive has a 1-year low of $57.41 and a 1-year high of $74.67.
Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, April 26th. The company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.66 by $0.01. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.86 billion. The company’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period last year, the business earned $0.74 EPS. As a group, sell-side analysts anticipate that Colgate-Palmolive will post 2.84 EPS for the current fiscal year.
In related news, CEO Noel R. Wallace sold 84,351 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $71.89, for a total value of $6,063,993.39. Following the sale, the chief executive officer now owns 279,023 shares of the company’s stock, valued at $20,058,963.47. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Ian M. Cook sold 19,500 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $71.28, for a total transaction of $1,389,960.00. Following the completion of the sale, the insider now directly owns 1,091,793 shares in the company, valued at approximately $77,823,005.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 342,684 shares of company stock worth $24,462,721. 1.14% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Capital Financial Planning LLC acquired a new stake in Colgate-Palmolive in the fourth quarter valued at approximately $27,000. Meridian Wealth Management LLC acquired a new stake in Colgate-Palmolive during the first quarter worth approximately $29,000. WP Advisors LLC acquired a new stake in Colgate-Palmolive during the first quarter worth approximately $34,000. Princeton Global Asset Management LLC acquired a new stake in Colgate-Palmolive during the first quarter worth approximately $43,000. Finally, Paragon Capital Management LLC acquired a new stake in Colgate-Palmolive during the first quarter worth approximately $46,000. 75.72% of the stock is currently owned by hedge funds and other institutional investors.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Recommended Story: Limitations of the P/E Growth ratio
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.